Beijing
China
Capital Medical University - Clinical and Research Center for Infectious Diseases
HIV, AIDS, nivolumab, pembrolizumab, avelumab, atezolizumab, durvalumab, anti-PD-1, anti-PD-L1
People living with HIV, inactivated SARS-CoV-2 vaccines, self-reported adverse events, neutralizing antibody responses against authentic SARS-CoV-2, total antibody specific to SARS-CoV-2, SARS-CoV-2 IgG antibody, antigen-specific T-cell immune response
HIV, low-level viraemia, prevalence, risk factors, virological failure